Table 2.

Randomised clinical trials and observational treatment studies

Authors, year, design	Number of 80+ years old	Number of years in follow-up	Mortality/outcome	Findings	Comments
Foody et al., 2006 [33], observational study	8,452	3 years	All-cause mortality	No association between statin discharge and all-cause mortality	Mortality after discharge diagnosis AMI
Heart Protection Study Collaborative Group, 2005 [30], RCTa	5,806 (70–80-year olds)	5 years	Total, vascular and non-vascular mortality	Statin allocation reduced vascular, all-cause but not non-vascular mortality significant	Participants had diabetes or vascular disease
Kjekshus, 2007 [31], RCT	2,064 (≥75-year olds)	3 years	Total and CVD mortality	No difference in total and CVD mortality in the statin and placebo groups	Participants had known systolic heart failure
MRC/BHF, 2002 [29], RCTa	5,806 (70–80-year olds), 1,263 (75–80-year olds)	5 years	Total and CVD mortality	Statin allocation reduced CVD and all-cause mortality among 70+-year old significant	Participants had diabetes or vascular disease
Shah et al., 2008 [34], observational study	3,779	3 years	All-cause mortality	Positive association between statin discharge and all-cause mortality	Mortality after discharge diagnosis HF
Shepherd et al., 2002 [32], RCT	5,804 (70–82-year olds), mean 75 years	3.2 years	Total and CHD mortality	Statin allocation not associated with all-cause mortality but positively with CHD mortality	High-risk participants

RCT, randomised clinical trial; AMI, acute myocardial infarction; HF, heart failure.

^aSame study population.